<code id='363A776CAB'></code><style id='363A776CAB'></style>
    • <acronym id='363A776CAB'></acronym>
      <center id='363A776CAB'><center id='363A776CAB'><tfoot id='363A776CAB'></tfoot></center><abbr id='363A776CAB'><dir id='363A776CAB'><tfoot id='363A776CAB'></tfoot><noframes id='363A776CAB'>

    • <optgroup id='363A776CAB'><strike id='363A776CAB'><sup id='363A776CAB'></sup></strike><code id='363A776CAB'></code></optgroup>
        1. <b id='363A776CAB'><label id='363A776CAB'><select id='363A776CAB'><dt id='363A776CAB'><span id='363A776CAB'></span></dt></select></label></b><u id='363A776CAB'></u>
          <i id='363A776CAB'><strike id='363A776CAB'><tt id='363A776CAB'><pre id='363A776CAB'></pre></tt></strike></i>

          entertainment

          entertainment

          author:focus    Page View:5236
          Mayo Clinic, in Rochester, Minnesota on
          Photo by KEREM YUCEL/AFP via Getty Images

          SAN FRANCISCO — Mayo Clinic has signed Silicon Valley tech startup Cerebras as its first generative AI partner, the health system announced Monday.

          The health system — known for its cutting-edge research and willingness to partner with tech companies — will give Cerebras millions of dollars to help build technology tools based on Mayo’s trove of de-identified patient data, leaders announced at the J.P. Morgan Healthcare Conference. Mayo and Cerebras did not disclose the dollar amount, but Cerebras said it was a multimillion, multi-year contract.

          advertisement

          With roughly 380 employees, Cerebras builds and sells supercomputers specifically designed for AI applications across several industries — pitting the upstart in direct competition with the market leader Nvidia Corp. Life sciences giants including GSK have used its technology for drug discovery, and it has partnered with a health network in United Arab Emirates, but this is Cerebras’ first AI contract with a U.S. health system. The deal gives Mayo access to Cerebras’ supercomputers as well as a Cerebras team to help develop health-tuned models; Mayo will then own whatever they build.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more

          AltruBio raises $225 million to develop ulcerative colitis drug

          Micrographofchronicactiveulcerativecolitisinabiopsyspecimen.WikimediaCommonsCheckpointinhibitors,dru